FindTrial
Sign In

Study on the relationship between tumor organoid drug sensitivity screening and multi-omics molecular typing

Study on the relationship between tumor organoid drug sensitivity screening and multi-omics molecular typing

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104750
Enrollment
Unknown
Registered
2025-06-23
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor

Interventions

Solid tumor patient group:None

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Subjects aged over 18 years. 2. Subjects with pathologically confirmed malignant tumors. 3. Subjects with accessible fresh tumor tissue or malignant effusion. 4. Subjects who voluntarily participate in this clinical trial, understand and comply with the study procedures, and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Subjects who are unable to obtain sufficient fresh tumor tissue or malignant effusion through surgery, biopsy, or puncture. 2. Subjects currently receiving other treatments that may affect the study. 3. Subjects who are pregnant. 4. Subjects who are incapacitated or have limited capacity. 5. Subjects with cognitive impairments. 6. Other situations deemed by the researcher as unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Success rate of tumor organoid modeling;—

Secondary

MeasureTime frame
Half inhibitory concentration;Multi-omics molecular typing;—

Countries

China

Contacts

Public ContactYingyong Hou

Zhongshan Hospital, Fudan University

houyingyong@aliyun.com+86 136 8197 2385

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026